Get the Stockscreener App
11.42
4.50%
0.492
Biohaven Ltd stock is traded at $11.42, with a volume of 634.18K.
It is up +4.50% in the last 24 hours and down -7.44% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$10.93
Open:
$10.95
24h Volume:
634.18K
Relative Volume:
0.32
Market Cap:
$1.73B
Revenue:
$737.54M
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.0145
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
-4.26%
1M Performance:
-7.44%
6M Performance:
+10.14%
1Y Performance:
-34.20%
1-Day Range:
$10.94
$11.66
1-Week Range:
$10.82
$12.27
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
11.42 | 1.73B | 737.54M | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-29-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Ono Pharmaceutical (TSE:4528) Secures Biohaven Asia Rights, Is The Stock Still A Bargain? - Simply Wall Street
Ono extends I&I reach in $100M Biohaven deal for IgG degraders - BioWorld News
Biohaven partners with Ono in $100m IgG degrader deal - Pharmaceutical Technology
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront - BigGo Finance
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement - Benzinga
Biohaven licenses IgG degrader portfolio to Ono for USD 80 million upfront - AllSci
Biohaven signs licensing deal with Japanese drugmaker worth up to $100M - Hartford Business Journal
Biohaven licenses IgG degrader portfolio to Japan’s Ono (BHVN:NYSE) - Seeking Alpha
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease - PR Newswire
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron? - Yahoo Finance
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development - GlobeNewswire Inc.
Roche’s AI lab; Biohaven’s pivotal pause - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Singapore
Biohaven’s cancer drug data selected for presentation at symposium - Investing.com
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - PR Newswire
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced? - Yahoo Finance
Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win - Law360
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 49.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap - simplywall.st
Biohaven (NYSE:BHVN)Stock Analysis - Simply Wall Street
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Faces New Securities Investigation - stl.news
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Why Is Biohaven (NYSE:BHVN) Opakalim Under FDA Hold on NYSE Composite? - Kalkine Media
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold - Yahoo Finance
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold By Investing.com - Investing.com South Africa
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Biohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trials - finance.biggo.com
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Why is Biohaven Pharmaceutical stock sliding today? - investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Nigeria
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com South Africa
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Canada
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com India
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Nigeria
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biohaven Ltd Stock (BHVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Buten Matthew | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,250 |
0 |
198,246 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
14,250 |
0 |
1,811,398 |
| Car Bruce | Chief Scientific Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,750 |
0 |
10,096 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
68,095 |
| Clark George C. | VP, Chief Accounting Officer |
Nov 17 '25 |
Buy |
8.52 |
17,000 |
144,770 |
20,000 |
| Bailey Gregory | Director |
Nov 13 '25 |
Buy |
7.50 |
400,000 |
3,000,000 |
2,020,071 |
| CHILDS JOHN W | Director |
Nov 13 '25 |
Buy |
7.50 |
3,333,333 |
24,999,998 |
5,653,904 |
| Coric Vlad | Chief Executive Officer |
Nov 13 '25 |
Buy |
7.50 |
666,666 |
4,999,995 |
1,195,275 |
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):